- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00868712
Warfarin and Coronary Calcification Project (WACC)
August 23, 2012 updated by: Todd C. Villines, Walter Reed Army Medical Center
The purpose of the study is to assess whether the use of warfarin, a commonly used anticoagulation drug, is associated with increased amounts of coronary artery calcification.
Studies in animals and preliminary but small retrospective studies in humans have suggested a possible link to increased tissue calcification with use of this drug.
The researchers will investigate this by assessing the amount of calcification seen in the coronary arteries using a specialized computed tomography (CT) scan (electron-beam CT) and assessing to see if the amount is influenced by the amount of time a patient has been taking warfarin.
The researchers will exclude patients with known coronary artery disease, chronic kidney disease or hyperparathyroidism.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
70
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20307
- Walter Reed Army Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients without known coronary heart disease, disorders of calcium metabolism or chronic kidney disease aged > 18 years who are referred to take or currently taking warfarin and are followed in the Anticoagulation Management Clinic at Walter Reed Army Medical Center (WRAMC).
Description
Inclusion Criteria:
- Age 18 years of age or older
- Patients referred to begin or already treated with warfarin anticoagulation therapy.
Exclusion Criteria:
- Known prior myocardial infarction or coronary heart disease
- History of advanced chronic kidney disease manifested by serum creatinine>2 or calculated glomerular filtration rate (GFR)<30
- History of hyperparathyroidism
- Current hypercalcemia
- Current hyperphosphatemia
- Uncertain duration of warfarin therapy
- Lack of records documenting international normalized ratio (INR) during therapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
1
Warfarin use < 6 months
|
2
Warfarin use 6-24 months
|
3
Warfarin use >24 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Coronary Calcification (Presence and Degree as Measured by Agatston Score) Attributed to Duration of Warfarin Use in Months After Controlling for Standard Cardiovascular Risk Factors to Include the Framingham Risk Score
Time Frame: EBCT scan is done at time of enrollment of patient into 1 of 3 groups based on warfarin use duration: <6 months; 6-24 months; >24 mos.
|
The Agatston score is calculated using a non-contrast computed tomography (CT) scan to measure for the presence and severity of coronary artery disease through identification of calcification in the coronary arteries.
Scores can range from 0 to several thousands.
The measure is without units.
Score categories are as follows: 0 = no coronary disease; 1-100 = low amount of coronary artery disease; 101-400 = moderately elevated score / moderate coronary artery disease; 401-1000 = severely elevated score; >1000 very severely elevated score.
Higher Agatston scores corelate with more coronary artery disease and predict a higher risk of coronary heart disease events and mortality.
|
EBCT scan is done at time of enrollment of patient into 1 of 3 groups based on warfarin use duration: <6 months; 6-24 months; >24 mos.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
International Normalized Ratio
Time Frame: EBCT scan is done at time of enrollment of patient into 1 of 3 groups based on warfarin use duration: <6 months; 6-24 months; >24 mos.
|
The International Normalized Ratio (INR) is a standardized lab value that measures the intensity of anticogulation using warfarin.
It is used to monitor patients taking warfarin.
|
EBCT scan is done at time of enrollment of patient into 1 of 3 groups based on warfarin use duration: <6 months; 6-24 months; >24 mos.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2004
Primary Completion (Actual)
January 1, 2010
Study Completion (Actual)
January 1, 2010
Study Registration Dates
First Submitted
March 24, 2009
First Submitted That Met QC Criteria
March 24, 2009
First Posted (Estimate)
March 25, 2009
Study Record Updates
Last Update Posted (Estimate)
August 24, 2012
Last Update Submitted That Met QC Criteria
August 23, 2012
Last Verified
August 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WU# 04-12020
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Calcification
-
Erasmus Medical CenterRecruitingVascular Calcification | Tomography, Optical Coherence | Treatment Outcome | Coronary Angiography | Humans | Vascular Calcification* / Diagnostic Imaging | Atherectomies, Coronary | Coronary Intervention, Percutaneous | Vascular Calcification* / TherapyNetherlands
-
RWTH Aachen UniversityCompletedCoronary Calcification | Valvular CalcificationGermany
-
Ramathibodi HospitalCompletedVascular Calcification | Coronary CalcificationThailand
-
Stanford UniversityRecruitingCoronary Artery CalcificationUnited States
-
University of Rome Tor VergataRecruitingCoronary Artery CalcificationItaly
-
National Heart Centre SingaporeBoston Scientific CorporationRecruitingCoronary Artery CalcificationSingapore, Japan
-
Assiut UniversityCompletedCoronary CalcificationNetherlands
-
Professor Fernando Figueira Integral Medicine InstituteFederal University of São PauloCompletedCoronary Artery Calcification | Vascular CalcificationBrazil
-
Medical University of SilesiaCompletedCoronary Artery Calcification | Stent Restenosis | Intravascular Lithotripsy | Stent Occlusion | Excimer Laser-coronary AtherectomyPoland, Italy
-
Centre Recherche Cardio Vasculaire AlpesRecruitingCoronary Calcification | AngiographyFrance